1. Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis
- Author
-
O. Bjørneboe, Elisabeth Lie, G.H. Brinkmann, Cathrine Thunem, M.D. Mjaavatten, E.S. Norli, Halvor Nygaard, Tore K Kvien, and Anne Julsrud Haugen
- Subjects
medicine.medical_specialty ,Inflammatory arthritis ,medicine.medical_treatment ,Immunology ,Population ,early rheumatoid arthritis ,Arthritis ,Osteoarthritis ,Early Arthritis ,outcomes research ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Internal medicine ,medicine ,Immunology and Allergy ,Reactive arthritis ,030212 general & internal medicine ,Disease-modifying antirheumatic drug ,education ,030203 arthritis & rheumatology ,education.field_of_study ,business.industry ,medicine.disease ,Rheumatoid arthritis ,Septic arthritis ,epidemiology ,business ,synovitis - Abstract
Objectives To describe the diagnostic spectrum, arthritis persistency and clinical outcomes after 2 years in patients with inflammatory arthritis (IA) of less than 16 weeks’ duration. Methods Data from the Norwegian Very Early Arthritis Clinic, a 2-year longitudinal observational study of adults with IA of ≤16 weeks’ duration, were used. Exclusion criteria were arthritis due to crystal deposits, trauma, osteoarthritis and septic arthritis. In all patients who had any follow-up information (population A), clinical diagnoses and persistency of arthritis were described. For patients with 2-year follow-up (population B), we also studied other clinical outcomes (disease activity, pain, fatigue, functional disability and health-related quality of life). Results In population A (n=1017) median (25th–75th percentile) duration of joint swelling was 35.0 (13.0–66.5) days, mean (SD) age 45.7 (14.8) years, 55.2% were females and 17.8% anticitrullinated protein antibodies positive. The most common final diagnoses were undifferentiated arthritis (UA) (41.7%), rheumatoid arthritis (RA) (24.1%) and reactive arthritis (18.1%). After 2 years, the arthritis had resolved in 59% of the patients. The remaining 41.0% had persistent disease defined by disease modifying antirheumatic drug (DMARD) use (32.1%) or persistent joint swelling without DMARD use (8.9%). In population B (n=669), all clinical outcomes improved significantly (P
- Published
- 2017